Advanced Cell Technology, Inc. (OTCBB: ACTC)

Download PDF

Symbol: OTCBB: ACTC

Address:
Corporate Headquarters
Advanced Cell Technology, Inc.
1201 Harbor Bay Parkway, Suite 120
Alameda, CA 94502
(510) 748-4900

www.advancedcell.com

Top Investment Highlights

Company made significant progress in macular degeneration indication by reporting positive data for its RPE cell animal study and entering into a collaboration with the Casey Eye Institute to conduct preclinical trials. Expects to file IND in 2007.
Announced milestone in its hemangioblast (HG) program by publishing article demonstrating hESC's ability to repair vascular damage in animals. Expects to file IND in 2008.
Company has a novel technique to generate embryonic stem cells that maintain the developmental potential of the embryo and, therefore, has the potential to shift ethical debate.
Company owns or licenses over 380 patents and patent applications related to the field of stem cell therapy.
Company is led by an experienced management team, including Dr. Michael D. West and Dr. Robert Lanza, two prominent experts in the field of regenerative medicine.
Company has growing legislative support: CA Prop.71 will provide $3 billion in funding over 10 years for stem cell research. Other states have passed or proposed similar legislation. New Congress elected 11/06 has promised to make stem cell research a priority.

Corporate Overview

Alameda, CA-based Advanced Cell Technology, Inc. is a biotechnology company applying human embryonic stem cell (hESC) technology in the field of regenerative medicine, a field focused on the development of new cells to replace those that are damaged or malfunctioning. Advanced Cell Technology plans to use its proprietary technology to develop treatments for diseases, including those of the eye, cardiovascular system, and skin - diseases which often have unmet medical needs. If successfully developed, the company's technologies may produce cells for the effective transplantation of diseased or destroyed cells in human patients. Advanced Cell Technology is one of a handful of US public companies in the field of regenerative medicine and stem cell technology.

Advanced Cell Technology recently announced a significant milestone in its hemangioblast (HG) program by reporting for the first time that hemangioblast precursor cells derived from hESC's can be used to achieve vascular repair. The research, which appeared online (ahead of print) in the journal Nature Methods, by the company and its collaborators, described an efficient method for generating large numbers of bipotential progenitors (hemangioblasts) from hESC's that are capable of differentiating into blood vessels as well as into all blood and immune cell lineages. The ability to repair vascular damage using these cells could have a profound impact on a large number of diseases that are major human afflictions. The company is committed to moving this technology from the laboratory into the clinic and plans on filing an Investigational New Drug Application (IND) with the Food and Drug Administration for the first clinical application of these cells by the end of 2008.

Technology

The study of stem cells has demonstrated their unique ability to serve as a template cell for the body. When taken from an embryo, these cells have the ability to produce any cell or tissue in the human body. Consequently, these cells may have the potential to treat, and even cure, a wide range of diseases and conditions, including cardiovascular disease, dermal trauma, eye disease, diabetes, and neurological diseases such as Alzheimer's and Parkinson's.

Advanced Cell Technology's developing technologies could provide cell-based therapies for applications in dermatology, blood diseases and cancer, macular degeneration and retinal pigmentosis, spinal cord injuries, and liver diseases such as hepatitis and cirrhosis. The company's scientists recently reported the generation of new lines of human embryonic stem cells that leave the developmental potential of the embryo intact by adapting a technique commonly used in fertility clinics to test for genetic disease. These cells were developed from a single blastomere (a type of cell from very early stage embryos), and the stem cell lines created were genetically normal and retained the ability to form multiple human cell types. Other techniques destroy the developmental potential of the embryo. Because Advanced Cell Technology's technique has the potential to leave the embryos unharmed, the technique may shift the ethical debate surrounding the embryonic stem cell research field.

Advanced Cell Technology's research programs include: (1) Cellular Reprogramming, which will enable to the transformation of a patient's own cells into ES cells, (2) a Reduced Complexity Library to enable the production of stem cell therapies that will treat acute diseases in time-critical situations, and (3) Stem Cell Differentiation to develop technologies that will control the differentiation and re-differentiation of stem cells into specific cell types.

Market and Target Applications

Retinal Pigment Epithelial (RPE) Cells - for degenerative disease of the eye

Market: over 10 million cases of macular degeneration in the US
Early lab testing of animals shows therapeutic potential
Collaboration with Casey Eye Institute for preclinical trials
IND expected to be filed in late 2007

Hemangioblast Cells - for multiple blood and cardiac disorders

Market: over 20 million cases of heart disease in the US
Published data in animal models shows strong therapeutic potential
Cells isolated in Massachusetts labs
Completing proof of concept studies with leading institutions
IND expected to be filed in 2008

Dermal Cells - for burns, wound repair and surgery

Wide range of applications with large target markets
Cells isolated in California labs
Focused on proof of concept studies with experts in the field
IND expected to be filed in 2008

Recent News

All of Advanced Cell's technologies are currently in the developmental or preclinical research stages. The company recently established the ability to rescue visual function in rats by implanting retinal pigment epithelial (RPE) cells derived from human ES cells. Advanced Cell also announced a collaboration with the Casey Eye Institute for preclinical trials. It expects to file its initial Investigational New Drug (IND) application for this RPE program late in 2007, after which the program will move into a human clinical trial.

Also, the company was recently awarded a federal grant from the National Institute of Health to accelerate embryonic stem cell research. In January 2007, Advanced Cell's CEO, William Caldwell, was interviewed on CNBC's "Power Lunch" and by Bloomberg Television.

Management

William M. Caldwell, IV, Chairman and CEO

Dr. Michael West, President and CSO

Dr. Robert Lanza, VP of Research and Scientific Development

Dr. Pedro Huertas, Chief Development Officer

Ivan Wolkind, VP of Finance and Chief Accounting Officer

Jon Atzen, SVP, General Council

This corporate profile is based upon information provided by management of Advanced Cell Technologies, Inc. The information is not intended to be and shall not constitute, an offer to sell or solicitation of any offer to buy any security. It is intended for information only and to increase awareness of Advanced Cell Technologies, Inc. services. Safe Harbor Statement: The statements in this document relating to future product availability, collaboration and partnership and positive direction are forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the aspects anticipated by these forward-looking statements may not, in fact, occur. Factors that could cause or contribute to such differences include, but are not limited to, contractual difficulties, demand for Advanced Cell Technologies, Inc.'s products, the future market price of Advanced Cell Technologies, Inc. common stock and the Company's ability to obtain necessary future financing. EQUITIES Magazine was paid by Advanced Cell Technologies, Inc. to write and print this profile. Before investing in any security, you are strongly advised to review all public filings of the issuer of such security, which can be found at www.sec.gov, as well as the warnings published by the Securities and Exchange Commission at http://www.sec.gov/investor.shtml.